Amy Kang1,2,3, Ria Arnold3, Martin Gallagher1,4, Paul Snelling5, Julianne Green6, Mangalee Fernando2,3, Matthew C Kiernan7,8, Samantha Hand4, Kim Grimley5, Jenny Burman4, Anne Heath6, Kris Rogers9,10, Amritendu Bhattacharya9, Brendan Smyth1,11,12, Thomas Bradbury1, Carmel Hawley13, Vlado Perkovic1,3, Arun V Krishnan3,14, Meg J Jardine. 1. Renal and Metabolic Division, The George Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia. 2. Department of Renal Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia. 3. Department of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia. 4. Department of Renal Medicine, Concord Hospital, Sydney, New South Wales, Australia. 5. Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 6. Department of Renal Medicine, Sydney Adventist Hospital, Sydney, New South Wales, Australia. 7. Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 8. Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia. 9. Statistics Division, The George Institute The George Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia. 10. Department of Statistics, University of Technology, Sydney, New South Wales, Australia. 11. Kidney Health Division, National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. 12. Department of Renal Medicine, St. George Hospital, Sydney, New South Wales, Australia. 13. Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia. 14. Department of Neurology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Neuropathy is a common complication of kidney disease that lacks proven disease-modifying treatments. Hemodiafiltration improves clearance of uremic toxins and is associated with better nerve function than hemodialysis. We aimed to determine whether hemodiafiltration reduces the progression of neuropathy in people receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE) study was an open-label, blinded end point assessment, controlled trial that randomized maintenance hemodialysis recipients to hemodiafiltration or high-flux hemodialysis for 48 months or until death or cessation of dialysis at four study centers. The primary outcome was the mean change in the yearly modified total neuropathy score from baseline, with time points weighted equally. RESULTS: A total of 124 participants were randomized and followed for a mean of 41 months. At baseline, neuropathy was present in 91 (73%) participants (modified total neuropathy score greater than or equal to two), and 38 (31%) had moderate to severe neuropathy (modified total neuropathy score 9-28). Convection volume in the hemodiafiltration arm was a median of 24.7 (interquartile range, 22.4-26.5) L. The mean modified total neuropathy score (SEM) worsened by 1.7 (0.4)/28 and 1.2 (0.4)/28 in the hemodiafiltration and hemodialysis groups, respectively, with a mean difference of 0.5 (95% confidence interval, -0.7 to 1.7; P=0.37). There was no difference in survival (hazard ratio, 1.24; 95% confidence interval, 0.61 to 2.51; log rank P=0.55) or any of the prespecified adverse events. There was no difference between groups in the number of participants who suffered an adverse event adjusted by follow-up time (relative risk, 1.05; 95% confidence interval, 0.83 to 1.32; P=0.68). CONCLUSIONS: Neuropathy is still a common complication of kidney disease without disease-altering therapy. Hemodiafiltration did not affect neuropathy progression compared with hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE), ACTRN12609000615280.
BACKGROUND AND OBJECTIVES: Neuropathy is a common complication of kidney disease that lacks proven disease-modifying treatments. Hemodiafiltration improves clearance of uremic toxins and is associated with better nerve function than hemodialysis. We aimed to determine whether hemodiafiltration reduces the progression of neuropathy in people receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE) study was an open-label, blinded end point assessment, controlled trial that randomized maintenance hemodialysis recipients to hemodiafiltration or high-flux hemodialysis for 48 months or until death or cessation of dialysis at four study centers. The primary outcome was the mean change in the yearly modified total neuropathy score from baseline, with time points weighted equally. RESULTS: A total of 124 participants were randomized and followed for a mean of 41 months. At baseline, neuropathy was present in 91 (73%) participants (modified total neuropathy score greater than or equal to two), and 38 (31%) had moderate to severe neuropathy (modified total neuropathy score 9-28). Convection volume in the hemodiafiltration arm was a median of 24.7 (interquartile range, 22.4-26.5) L. The mean modified total neuropathy score (SEM) worsened by 1.7 (0.4)/28 and 1.2 (0.4)/28 in the hemodiafiltration and hemodialysis groups, respectively, with a mean difference of 0.5 (95% confidence interval, -0.7 to 1.7; P=0.37). There was no difference in survival (hazard ratio, 1.24; 95% confidence interval, 0.61 to 2.51; log rank P=0.55) or any of the prespecified adverse events. There was no difference between groups in the number of participants who suffered an adverse event adjusted by follow-up time (relative risk, 1.05; 95% confidence interval, 0.83 to 1.32; P=0.68). CONCLUSIONS: Neuropathy is still a common complication of kidney disease without disease-altering therapy. Hemodiafiltration did not affect neuropathy progression compared with hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE), ACTRN12609000615280.
Authors: Hugh Bostock; Richard J L Walters; Kjeld V Andersen; Nicholas M F Murray; David Taube; Matthew C Kiernan Journal: Nephrol Dial Transplant Date: 2004-02-19 Impact factor: 5.992
Authors: B Canaud; J L Bragg-Gresham; M R Marshall; S Desmeules; B W Gillespie; T Depner; P Klassen; F K Port Journal: Kidney Int Date: 2006-06 Impact factor: 10.612
Authors: E Lars Penne; Neelke C van der Weerd; Michiel L Bots; Marinus A van den Dorpel; Muriel P C Grooteman; Renée Lévesque; Menso J Nubé; Piet M Ter Wee; Peter J Blankestijn Journal: Nephrol Dial Transplant Date: 2009-06-10 Impact factor: 5.992
Authors: Ria Arnold; Timothy J Pianta; Bruce A Pussell; Adrienne Kirby; Kate O'Brien; Karen Sullivan; Margaret Holyday; Christine Cormack; Matthew C Kiernan; Arun V Krishnan Journal: Clin J Am Soc Nephrol Date: 2017-09-11 Impact factor: 8.237